188 related articles for article (PubMed ID: 30249425)
1. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2018 Oct; 36(45):6810-6818. PubMed ID: 30249425
[TBL] [Abstract][Full Text] [Related]
2. Herpes zoster related healthcare burden and costs in immunocompromised (IC) and IC-free populations in England: an observational retrospective database analysis.
Curran D; Hunjan M; El Ghachi A; El-Hahi Y; Bianco V; Ferreira G
BMJ Open; 2019 Aug; 9(8):e023502. PubMed ID: 31462457
[TBL] [Abstract][Full Text] [Related]
3. Costs of herpes zoster complications in older adults: A cohort study of US claims database.
Meyers JL; Candrilli SD; Rausch DA; Yan S; Patterson BJ; Levin MJ
Vaccine; 2019 Feb; 37(9):1235-1244. PubMed ID: 30685248
[TBL] [Abstract][Full Text] [Related]
4. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012.
Yanni EA; Ferreira G; Guennec M; El Hahi Y; El Ghachi A; Haguinet F; Espie E; Bianco V
BMJ Open; 2018 Jun; 8(6):e020528. PubMed ID: 29880565
[TBL] [Abstract][Full Text] [Related]
5. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
6. Herpes zoster risk and burden of disease in immunocompromised populations: a population-based study using health system integrated databases, 2009-2014.
Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Orrico-Sánchez A
BMC Infect Dis; 2020 Nov; 20(1):905. PubMed ID: 33256624
[TBL] [Abstract][Full Text] [Related]
7. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
8. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
[No Abstract] [Full Text] [Related]
9. Healthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study.
Mao J; McPheeters JT; Finelli L
Medicine (Baltimore); 2017 Dec; 96(48):e8746. PubMed ID: 29310348
[TBL] [Abstract][Full Text] [Related]
10. Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.
Insinga RP; Itzler RF; Pellissier JM
Pharmacoeconomics; 2007; 25(2):155-69. PubMed ID: 17249857
[TBL] [Abstract][Full Text] [Related]
11. Cost of shingles: population based burden of disease analysis of herpes zoster and postherpetic neuralgia.
Friesen KJ; Chateau D; Falk J; Alessi-Severini S; Bugden S
BMC Infect Dis; 2017 Jan; 17(1):69. PubMed ID: 28086817
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs associated with herpes zoster in the US.
Johnson BH; Palmer L; Gatwood J; Lenhart G; Kawai K; Acosta CJ
J Med Econ; 2016 Oct; 19(10):928-35. PubMed ID: 27149530
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant.
Mao J; McPheeters JT; Zhang D; Acosta CJ; Finelli L
Curr Med Res Opin; 2018 Apr; 34(4):741-749. PubMed ID: 28945107
[TBL] [Abstract][Full Text] [Related]
14. Herpes zoster-attributable resource utilization and cost burden in patients with solid organ transplant.
Palmer L; White RR; Johnson BH; Fowler R; Acosta CJ
Transplantation; 2014 Jun; 97(11):1178-84. PubMed ID: 24892964
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Resource Utilisation Associated with Herpes Zoster in a Prospective Cohort of Older Australian Adults.
Karki S; Newall AT; MacIntyre CR; Heywood AE; McIntyre P; Banks E; Liu B
PLoS One; 2016; 11(8):e0160446. PubMed ID: 27483007
[TBL] [Abstract][Full Text] [Related]
17. Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost.
Singer D; Thompson-Leduc P; Ma S; Gupta D; Cheng WY; Muthukumar A; Devine F; Sundar M; Bogart M; Hagopian E; Poston S; Duh MS; Oppenheimer JJ
BMJ Open Respir Res; 2024 Jun; 11(1):. PubMed ID: 38862238
[TBL] [Abstract][Full Text] [Related]
18. Incidence of herpes zoster and its complications in Germany, 2005-2009.
Hillebrand K; Bricout H; Schulze-Rath R; Schink T; Garbe E
J Infect; 2015 Feb; 70(2):178-86. PubMed ID: 25230396
[TBL] [Abstract][Full Text] [Related]
19. The temporal impact of aging on the burden of herpes zoster.
Varghese L; Standaert B; Olivieri A; Curran D
BMC Geriatr; 2017 Jan; 17(1):30. PubMed ID: 28114907
[TBL] [Abstract][Full Text] [Related]
20. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
